Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.

Pasquale Mone,Angela Lombardi,Jessica Gambardella,Antonella Pansini,Gaetano Macina,Maria Morgante,Salvatore Frullone,Gaetano Santulli

Diabetes care（2022）

引用 53|浏览2

暂无评分

摘要

This study is the first to show significant beneficial effects of the SGLT2 inhibitor empagliflozin on cognitive and physical impairment in frail older adults with diabetes and HFpEF.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要